|
Volumn 19, Issue 1, 2002, Pages 63-66
|
Could publication of bioinequivalence data discourage frauds on bioequivalence trials?
a a
a
IPAS
(United States)
|
Author keywords
Bioequivalence; Bioinequivalence; Frauds; Generic drugs
|
Indexed keywords
CARBAMAZEPINE;
CLOZAPINE;
DIAZEPAM;
DIGOXIN;
DILTIAZEM;
ESTROGEN DERIVATIVE;
GENERIC DRUG;
HYDROCHLOROTHIAZIDE;
ARTICLE;
BIOEQUIVALENCE;
DRUG ACTIVITY;
DRUG FORMULATION;
DRUG MARKETING;
DRUG QUALITY;
EUROPE;
FORGERY;
HUMAN;
INTERNATIONAL COOPERATION;
LAW;
PUBLICATION;
SYSTEMIC DISEASE;
TOXICITY TESTING;
UNITED STATES;
|
EID: 0036275666
PISSN: 10601333
EISSN: None
Source Type: Journal
DOI: 10.1081/CRP-120004217 Document Type: Article |
Times cited : (1)
|
References (17)
|